Moderna announced Monday that it is starting to administer its next-generation COVID-19 vaccine candidate in a Phase 1 study. The new candidate, mRNA-1283, can be stored in a refrigerator, which could potentially facilitate storage and shipping barriers.
“We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283,” Moderna CEO Stephane Bancel said in a press release on Monday. “Our investments in our mRNA platform have enabled us to develop this next-generation vaccine candidate, which is a potential refrigerator-resistant vaccine that can facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries. committed to helping address this ongoing public health emergency.
The new clinical trial is to evaluate three dose levels of the mRNA-1283, which targets the SARS-CoV-2 ear protein, given to healthy adults in a two-dose series 28 days apart and at one dose level in ‘ is a single shot.
(iStock)
The currently approved Moderna two-dose vaccine can be stored in the refrigerator for up to 30 days before use, between 2 degrees Celsius and 8 degrees Celsius, but cannot be frozen again once thawed. Unlimited bottles can be stored for up to 8 hours between 8 degrees Celsius and 25 Celsius, but can also not be frozen again.
‘PARTIAL’ PFIZER COVID-19 INCLUSION INSECTION RISK WITH 63% OF NURSES IN NURSING:
The new clinical trial is to evaluate three dose levels of the mRNA-1283, which targets the SARS-CoV-2 ear protein, given to healthy adults in a two-dose series 28 days apart and at one dose level in ‘ is a single shot. The results will be compared with the current authorized dose level in the two-dose range.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
“mRNA-1283 is intended to be evaluated in future studies for use as a booster dose for previously vaccinated or seropositive, as well as in a primary series for seregative individuals,” the press release reads.